Alessandro Pastorino was born in Genoa (Italy), on July 29, 1985.

He received his MD Degree in 2010 and his Specialty Degree in Medical Oncology in 2016 from the University of Genoa, Italy.

Since 2016, he is a Medical Oncologist in the Medical Oncology and Hematology Department at Sant’Andrea Hospital in La Spezia - Italy.

His clinical activity is mainly dedicated to the treatment of gastrointestinal malignancies and his clinical research is mostly focused on colon, pancreatic and gastric cancer.

Alessandro Pastorino conducted more than 40 pivotal international clinical trials as sub-investigator. The most important are listed as follows:

• CORRECT trial: Regorafenib versus placebo/BSC in metastatic colorectal cancer in progression of disease after standard treatments.
• TOSCA trial: Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer.
• RECOURSE trial: Tas-102 plus best supportive care (BSC) versus placebo plus BSC in patients with metastatic colocorectal cancer refractory to standard chemotherapies.
• RAINBOW trial: Weekly Paclitaxel with or without Ramucirumab (IMC-1121B) drug product in patients with metastatic gastric Adenocarcinoma, refractory to or progressive after first-line therapy with Platinum and Fluoropyrimide.
• REACH trial: Ramucirumab versus placebo as Second-line treatment in patients with Hepatocellular carcinoma following First-line therapy with Sorafenib.
• LAPACT trial: Nab-paclitaxel plus Gemcitabine in subjects with locally advanced pancreatic cancer.
• RESARCH trial. Non-operative management in rectal cancer achieving clinical complete response after neoadjuvant chemoradiotherapy.

In 2015 the collaboration with Prof Sobrero led to the publication of the paper “ Raising the bar for antineoplastic agents: how to choose threshold values for superiority trials in advanced solid tumours”.

Currently, Dr Pastorino is an active member of multidisciplinary tumour boards for the treatment of gastrointestinal cancers with particular management experience in rectal and anal carcinomas. His clinical efforts are now mostly focused on non-operative management of rectal cancer in complete clinical response after preoperative treatment.

Alessandro Pastorino is an active member of the Italian Association of Medical Oncology (AIOM). Since 2017 he is the Scientific Secretary of AIOM Guidelines for the treatment of Rectal and Anal carcinoma and he was invited speaker in more than 20 national meetings in GI oncology.